Q-omics provides the consensus-scored REST profile across patient tissues and cancer cell-line models. REST expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, REST is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, REST protein abundance shows 27,227 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where REST shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REST — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REST survival associations across molecular data types. REST RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REST RNA expression–survival associations across cancer types. High REST expression shows unfavorable associations in CESC and LGG, but favorable associations in KIRC, UCS, HNSC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for REST RNA expression.
This table summarizes REST tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for REST. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REST shows lower tumor expression in KIRC and higher tumor expression in HNSC, LIHC, BRCA, LUSC and CHOL. The HNSC box plot shows higher REST RNA expression in tumor versus normal tissue (log2 FC = +0.665, t-test p < 0.001).
This table shows molecular features associated with REST in patient tissues and cancer cell lines. In patient samples, REST shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, REST RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
